| __timestamp | Catalent, Inc. | Intra-Cellular Therapies, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 334800000 | 10337679 |
| Thursday, January 1, 2015 | 337300000 | 18187286 |
| Friday, January 1, 2016 | 358100000 | 24758063 |
| Sunday, January 1, 2017 | 402600000 | 23666957 |
| Monday, January 1, 2018 | 462600000 | 30099855 |
| Tuesday, January 1, 2019 | 512000000 | 64947625 |
| Wednesday, January 1, 2020 | 577900000 | 186363444 |
| Friday, January 1, 2021 | 687000000 | 272611040 |
| Saturday, January 1, 2022 | 844000000 | 358782000 |
| Sunday, January 1, 2023 | 831000000 | 409864000 |
| Monday, January 1, 2024 | 935000000 |
Igniting the spark of knowledge
In the competitive landscape of the pharmaceutical industry, operational efficiency is key. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent players: Catalent, Inc. and Intra-Cellular Therapies, Inc., from 2014 to 2023.
Catalent, Inc. has shown a steady increase in SG&A expenses, peaking at approximately 935 million in 2024, reflecting a growth of nearly 180% over the decade. This trend underscores Catalent's expansive operational strategies and market reach. In contrast, Intra-Cellular Therapies, Inc. has experienced a more dramatic rise, with expenses surging from around 10 million in 2014 to over 400 million in 2023, marking an exponential growth of over 3,800%. This rapid increase highlights the company's aggressive investment in market penetration and innovation.
While Catalent's expenses plateaued in 2023, Intra-Cellular's data for 2024 remains elusive, leaving room for speculation on future strategies.
Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Intra-Cellular Therapies, Inc.
Operational Costs Compared: SG&A Analysis of GSK plc and Intra-Cellular Therapies, Inc.
Operational Costs Compared: SG&A Analysis of Takeda Pharmaceutical Company Limited and Catalent, Inc.
Intra-Cellular Therapies, Inc. vs Summit Therapeutics Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Intra-Cellular Therapies, Inc. and Bio-Techne Corporation
Cost Management Insights: SG&A Expenses for Intra-Cellular Therapies, Inc. and Ascendis Pharma A/S
Intra-Cellular Therapies, Inc. and TG Therapeutics, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Intra-Cellular Therapies, Inc. vs Verona Pharma plc
Intra-Cellular Therapies, Inc. vs ADMA Biologics, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Intra-Cellular Therapies, Inc. vs Geron Corporation Trends and Insights
Intra-Cellular Therapies, Inc. vs Xencor, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Catalent, Inc. or Dynavax Technologies Corporation